Immunotherapy added to chemotherapy improves pathological complete response in patients with early triple-negative breast cancer, according to late-breaking results from the KEYNOTE-522 trial presented by Prof. Peter Schmid (Queen Mary University of London, UK) . Interim results from the study, which is the first phase 3 trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.
KEYNOTE-522 tested whether adding immunotherapy to chemotherapy prior to surgery could improve pathological complete response and event-free survival in women with early triple-negative breast cancer. A total of 1,174 patients were randomly allocated at a 2:1 ratio to pembrolizumab or placebo, both added to preoperative chemotherapy with anthracyclines, taxanes, and platinum for 5-6 months. After surgery, patients continued their allocated treatment of pembrolizumab or placebo...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Long-term data from CheckMate 067 Next Article
Preoperative chemotherapy for colon cancer »
Table of Contents: ESMO 2019
Solid tumours/pan-tumour data
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.